TAS-102-话题@MedSci - 梅斯（MedSci）

#TAS-102#

12篇内容 | 1218人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1661533, encodeId=11781661533a2, content=<a href='/topic/show?id=706f1e139a8' target=_blank style='color:#2F92EE;'>#TAS-102#</a>, objectTitle=Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期, objectType=article, longId=187111, objectId=646618e11101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=646618e11101, replyNumber=0, likeNumber=74, createdTime=2020-05-08, rootId=0, userName=ms8435843352634314, userId=7cb525318216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=646618e11101, moduleTitle=Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=646618e11101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661532, encodeId=9a9b166153245, content=<a href='/topic/show?id=706f1e139a8' target=_blank style='color:#2F92EE;'>#TAS-102#</a>, objectTitle=FTD（TAS-102）后线治疗晚期胃癌疗效与安全性并优, objectType=article, longId=168155, objectId=2445168155ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2445168155ce, replyNumber=0, likeNumber=68, createdTime=2020-01-11, rootId=0, userName=ms8435843352634314, userId=7cb525318216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2445168155ce, moduleTitle=FTD（TAS-102）后线治疗晚期胃癌疗效与安全性并优, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2445168155ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661531, encodeId=c262166153102, content=<a href='/topic/show?id=706f1e139a8' target=_blank style='color:#2F92EE;'>#TAS-102#</a>, objectTitle=消化道肿瘤新药:TAS-102,再下一城, objectType=article, longId=140144, objectId=f893140144b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f893140144b7, replyNumber=0, likeNumber=82, createdTime=2018-09-04, rootId=0, userName=ms8435843352634314, userId=7cb525318216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f893140144b7, moduleTitle=消化道肿瘤新药:TAS-102,再下一城, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f893140144b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661527, encodeId=bb9c166152e7f, content=<a href='/topic/show?id=706f1e139a8' target=_blank style='color:#2F92EE;'>#TAS-102#</a>, objectTitle=Lancet Oncol：TAS-102+贝伐单抗可用于治疗难治性的转移性结直肠癌, objectType=article, longId=107145, objectId=3c8510e145e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c8510e145e7, replyNumber=0, likeNumber=87, createdTime=2017-09-14, rootId=0, userName=ms8435843352634314, userId=7cb525318216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c8510e145e7, moduleTitle=Lancet Oncol：TAS-102+贝伐单抗可用于治疗难治性的转移性结直肠癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3c8510e145e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661528, encodeId=120216615289d, content=<a href='/topic/show?id=706f1e139a8' target=_blank style='color:#2F92EE;'>#TAS-102#</a>, objectTitle=Lancet Oncol：C-TASK FORCE研究：TAS-102 联合贝伐单抗有效治疗难治性转移性结直肠癌, objectType=article, longId=107858, objectId=4df710e8587e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4df710e8587e, replyNumber=0, likeNumber=95, createdTime=2017-12-20, rootId=0, userName=ms8435843352634314, userId=7cb525318216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4df710e8587e, moduleTitle=Lancet Oncol：C-TASK FORCE研究：TAS-102 联合贝伐单抗有效治疗难治性转移性结直肠癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4df710e8587e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661530, encodeId=5fe4166153099, content=<a href='/topic/show?id=706f1e139a8' target=_blank style='color:#2F92EE;'>#TAS-102#</a>, objectTitle=EUR J Cancer：治疗结直肠癌患者的III期RECOURSE临床试验的亚组中 trifluridine / tipiracil（TAS-102）与安慰剂, objectType=article, longId=124746, objectId=df36124e4632, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df36124e4632, replyNumber=0, likeNumber=89, createdTime=2018-08-28, rootId=0, userName=ms8435843352634314, userId=7cb525318216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df36124e4632, moduleTitle=EUR J Cancer：治疗结直肠癌患者的III期RECOURSE临床试验的亚组中 trifluridine / tipiracil（TAS-102）与安慰剂, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=df36124e4632)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661529, encodeId=b86b166152948, content=<a href='/topic/show?id=706f1e139a8' target=_blank style='color:#2F92EE;'>#TAS-102#</a>, objectTitle=Lancet Oncol:TAS-102 联合贝伐单抗有效治疗难治性转移性结直肠癌, objectType=article, longId=107861, objectId=776510e86195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=776510e86195, replyNumber=0, likeNumber=70, createdTime=2017-10-22, rootId=0, userName=ms8435843352634314, userId=7cb525318216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=776510e86195, moduleTitle=Lancet Oncol:TAS-102 联合贝伐单抗有效治疗难治性转移性结直肠癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=776510e86195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661526, encodeId=2dd71661526f1, content=<a href='/topic/show?id=706f1e139a8' target=_blank style='color:#2F92EE;'>#TAS-102#</a>, objectTitle=FDA批准TAS-102(Lonsurf)用于治疗晚期结直肠癌, objectType=article, longId=56824, objectId=8f225682468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f225682468, replyNumber=0, likeNumber=90, createdTime=2015-10-06, rootId=0, userName=ms8435843352634314, userId=7cb525318216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f225682468, moduleTitle=FDA批准TAS-102(Lonsurf)用于治疗晚期结直肠癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8f225682468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661525, encodeId=b036166152504, content=<a href='/topic/show?id=706f1e139a8' target=_blank style='color:#2F92EE;'>#TAS-102#</a>, objectTitle=NEJM：TAS-102对难治性转移性结直肠癌的临床效果, objectType=article, longId=50749, objectId=cb8350e49b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb8350e49b1, replyNumber=0, likeNumber=74, createdTime=2015-09-14, rootId=0, userName=ms8435843352634314, userId=7cb525318216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb8350e49b1, moduleTitle=NEJM：TAS-102对难治性转移性结直肠癌的临床效果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cb8350e49b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661524, encodeId=181116615248b, content=<a href='/topic/show?id=706f1e139a8' target=_blank style='color:#2F92EE;'>#TAS-102#</a>, objectTitle=RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者, objectType=article, longId=43695, objectId=811c4369574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=811c4369574, replyNumber=0, likeNumber=87, createdTime=2015-02-10, rootId=0, userName=ms8435843352634314, userId=7cb525318216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=811c4369574, moduleTitle=RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=811c4369574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661523, encodeId=426c166152351, content=<a href='/topic/show?id=706f1e139a8' target=_blank style='color:#2F92EE;'>#TAS-102#</a>, objectTitle=TAS-102能提高转移性结肠癌患者的存活率, objectType=article, longId=37287, objectId=139a3e28729, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=139a3e28729, replyNumber=0, likeNumber=203, createdTime=2014-12-09, rootId=0, userName=ms8435843352634314, userId=7cb525318216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=139a3e28729, moduleTitle=TAS-102能提高转移性结肠癌患者的存活率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=139a3e28729)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661522, encodeId=98ca1661522a6, content=<a href='/topic/show?id=706f1e139a8' target=_blank style='color:#2F92EE;'>#TAS-102#</a>, objectTitle=Lancet Oncol：新药TAS-102治疗晚期大肠癌效果较好, objectType=article, longId=9431, objectId=e4ee943140, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4ee943140, replyNumber=0, likeNumber=74, createdTime=2013-05-11, rootId=0, userName=ms8435843352634314, userId=7cb525318216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4ee943140, moduleTitle=Lancet Oncol：新药TAS-102治疗晚期大肠癌效果较好, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e4ee943140)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TAS-102

2020-05-29

ms8435843352634314 (审核中...)

前往app查看评论内容

#TAS-102#

Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期

2020-05-08

ms8435843352634314 (审核中...)

前往app查看评论内容

#TAS-102#

FTD（TAS-102）后线治疗晚期胃癌疗效与安全性并优

2020-01-11

ms8435843352634314 (审核中...)

前往app查看评论内容

#TAS-102#

消化道肿瘤新药:TAS-102,再下一城

2018-09-04

ms8435843352634314 (审核中...)

前往app查看评论内容

#TAS-102#

Lancet Oncol：TAS-102+贝伐单抗可用于治疗难治性的转移性结直肠癌

2017-09-14

ms8435843352634314 (审核中...)

前往app查看评论内容

#TAS-102#

Lancet Oncol：C-TASK FORCE研究：TAS-102 联合贝伐单抗有效治疗难治性转移性结直肠癌

2017-12-20

ms8435843352634314 (审核中...)

前往app查看评论内容

#TAS-102#

EUR J Cancer：治疗结直肠癌患者的III期RECOURSE临床试验的亚组中 trifluridine / tipiracil（TAS-102）与安慰剂

2018-08-28

ms8435843352634314 (审核中...)

前往app查看评论内容

#TAS-102#

Lancet Oncol:TAS-102 联合贝伐单抗有效治疗难治性转移性结直肠癌

2017-10-22

ms8435843352634314 (审核中...)

前往app查看评论内容

#TAS-102#

FDA批准TAS-102(Lonsurf)用于治疗晚期结直肠癌

2015-10-06

ms8435843352634314 (审核中...)

前往app查看评论内容

#TAS-102#

NEJM：TAS-102对难治性转移性结直肠癌的临床效果

2015-09-14

ms8435843352634314 (审核中...)

前往app查看评论内容

#TAS-102#

RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者

2015-02-10

ms8435843352634314 (审核中...)

前往app查看评论内容

#TAS-102#

TAS-102能提高转移性结肠癌患者的存活率

2014-12-09

ms8435843352634314 (审核中...)

前往app查看评论内容

#TAS-102#

Lancet Oncol：新药TAS-102治疗晚期大肠癌效果较好

2013-05-11

科室
- - 订阅+
  - 更多科室
工具
服务